ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/paediatric-and-aya/paediatric-cancers/all
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Paediatric cancers / All
52
trial(s) found.
NCT07334301
Paed
Phase 1 / Phase 2
Recruiting
A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma (
BEACON2
)
Bevacizumab
Dinutuximab
Irinotecan
Temozolomide
Topotecan
alkylating agent
anti-GD2 monoclonal antibody
anti-VEGF monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
immuno-oncology therapy,VEGF-targeting
topoisomerase inhibitor
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT07109219
Paed
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of AZD4512 Monotherapy or in Combination With Anticancer Agent(s) in Participants With Acute Lymphoblastic Leukemia (
ALLight
)
anti-CD22 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06876649
Paed
Phase 4
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
BTK inhibitor
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06838676
Paed
Phase 2
Recruiting
A Phase II Trial of ACT001 in Children and Adolescents With Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas (
CONNECT2110
)
NFKB inhibitor
Diffuse intrinsic pontine glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT06514794
Paed
Phase 2
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex) (
WUC007-03
)
allogeneic CAR-T-cell therapy,CD7-targeting
Lymphoma
T-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3052 - Parkville - Royal Children's Hospital Melbourne
NCT06414148
Paed
Phase 2
Recruiting
A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (
EpLCART
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
immunomodulatory imide drug
Diffuse large B-cell lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06413706
Paed
Phase 2
Recruiting
A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy
CDK4/6 inhibitor
alkylating agent
radiotherapy
Glioma
NSW
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT06395103
Paed
Phase 1 / Phase 2
Recruiting
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (
9999-01A
)
anti-ROR1 antibody-drug conjugate
B-cell acute lymphoblastic leukaemia/lymphoma
Burkitt lymphoma
Diffuse large B-cell lymphoma
Ewing sarcoma
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
NCT06381570
Paed
Phase 0
Recruiting
VICTORY
: A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine With Oral Type II RAF Inhibitor Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
RAF inhibitor,type 2
vinca alkaloid
Low-grade glioma
NCT06302426
Paed
Phase 1
Not yet recruiting
An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours (
INI-4001-101
)
TLR7/TLR8 agonist
Solid tumour
NSW
2640 - Albury - Border Medical Oncology Research Unit
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
NCT06208657
Paed
Phase 1 / Phase 2
Recruiting
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer (
OPTIMISE
)
Irinotecan
Nivolumab
PI3K alpha inhibitor
PI3K delta inhibitor
PI3K inhibitor
Paxalisib
Relatlimab
Temozolomide
alkylating agent
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3K delta-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
topoisomerase inhibitor
Cancer
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06161974
Paed
Phase 2
Recruiting
Phase 2 Study of Olutasidenib with Temozolomide As Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations (
TarGeT-D
)
IDH1 R132 inhibitor
alkylating agent
Astrocytoma
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
Glioma
H3K27M-mutant glioma
High-grade glioma
Oligodendroglioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT06137118
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of AZD0486 in Adolescent and Adult Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (
SYRUS
)
bispecific T-cell engager,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06124157
Paed
Phase 3
Recruiting
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia (
NCI-2023-09214
)
bispecific T-cell engager,CD19-targeting
Acute lymphoblastic leukaemia
WA
6009 - Perth - Perth Children's Hospital
NCT05999994
Paed
Phase 2
Recruiting
CAMPFIRE
: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Abemaciclib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Cyclophosphamide
Docetaxel
Gemcitabine
Irinotecan
Ramucirumab
Temozolomide
Vinorelbine
alkylating agent
anti-VEGFR2 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,VEGFR2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,VEGFR2-targeting
taxane
topoisomerase inhibitor
vinca alkaloid
Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05991388
Paed
Phase 2 / Phase 3
Recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (
Glo-BNHL
)
Carboplatin
Dexamethasone
Etoposide
Ifosfamide
Loncastuximab Tesirine
Odronextamab
Rituximab
alkylating agent
anti-CD19 antibody-drug conjugate
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
cancer therapy
cancer therapy,CD19-targeting
cancer therapy,CD20-targeting
cytotoxic chemotherapy
glucocorticoid
immuno-oncology therapy,CD19-targeting
immuno-oncology therapy,CD20-targeting
platinum-based antineoplastic agent
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Non-Hodgkin's lymphoma
NSW
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05843253
Paed
Phase 2
Recruiting
Phase 2 Study of Ribociclib-Containing Post-Radiotherapy Combinations in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma: Ribociclib and Everolimus for HGG/DIPG Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways AND Ribociclib and Temozolomide for DHG, H3G34-mutant (
CONNECT-TarGeT-A
)
CDK4/6 inhibitor
alkylating agent
mTORC1 inhibitor
radiotherapy
Anaplastic astrocytoma
Central nervous system cancer
Diffuse hemispheric glioma
Diffuse intrinsic pontine glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05839379
Paed
Recruiting
Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed With High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma (
CONNECT-TarGeT-SCR
)
Anaplastic astrocytoma
Central nervous system cancer
Diffuse intrinsic pontine glioma
Glioblastoma
Glioma
H3K27M-mutant glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05566795
Paed
Phase 3
Recruiting
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy (
DAY101-002
)
RAF inhibitor,type 2
Fibrosarcoma
Glioma
Low-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05533775
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (
iMATRIX-GLO
)
bispecific T-cell engager,CD20-targeting
Non-Hodgkin's lymphoma
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05504291
Paed
Phase 2
Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma (
ARET2121
)
alkylating agent
Retinoblastoma
WA
6009 - Perth - Perth Children's Hospital
NCT05453903
Paed
Phase 1
Recruiting
A Phase 1b Study of Bleximenib in Combination With AML-Directed Therapies for Participants With Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations (
CR109124
)
KMT2A inhibitor
Acute myeloid leukaemia
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
NCT05327894
Paed
Phase 3
Recruiting
Interfant-21
International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.
Blinatumomab
Prednisone
bispecific T-cell engager,CD19-targeting
cancer therapy
cancer therapy,CD19-targeting
glucocorticoid
immuno-oncology therapy,CD19-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
Acute lymphoblastic leukaemia
Mixed phenotype acute leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NA
8011 - Christchurch - Christchurch Children's Hospital
NCT05304585
Paed
Phase 3
Recruiting
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma (
ARST2032
)
Cyclophosphamide
Dactinomycin
Radiotherapy
Vincristine
alkylating agent
antineoplastic antibiotic
cancer therapy
cytotoxic chemotherapy
vinca alkaloid
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05269771
Paed
No longer available
Treatment Plan for Managed Access Program (MAP) to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (PV) (
CINC424B2002I
)
JAK1/JAK2 inhibitor
Polycythemia vera
NSW
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
NCT05230758
Paed
Phase 3
Recruiting
Phase III Randomized Double-blind Placebo-controlled Trial of Metformin for Cognitive Recovery and White Matter Growth in Paediatric Patients With a Brain Tumour (
Met-Med-Can
)
biguanide antihyperglycaemic agent
placebo
Medulloblastoma
NSW
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (WITHDRAWN)
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT05183035
Paed
Phase 3
Recruiting
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML (
ITCC-101-APAL2020D
)
Bcl2 inhibitor
anti-CD33 antibody-drug conjugate
antimetabolite
Acute myeloid leukaemia
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT05024929
Paed
Recruiting
Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Differentiated Thyroid Cancer (
21-018612
)
Differentiated thyroid carcinoma
Papillary thyroid cancer
NSW
2145 - Westmead - The Children's Hospital at Westmead
NCT04884035
Paed
Phase 1
Recruiting
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma (
CC-220-DLBCL-001
)
CELMoD agent
Lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (COMPLETED)
WA
6000 - Perth - Royal Perth Hospital (COMPLETED)
NCT04870944
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma (
PEPN2111
)
curaxin,FACT complex-targeting
Cancer
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Lymphoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital (SUSPENDED)
NCT04811560
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (
cAMeLot-1
)
KMT2A inhibitor
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Leukaemia
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04775485
Paed
Phase 2
Recruiting
FIREFLY-1
: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
RAF inhibitor,type 2
Low-grade glioma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT04774718
Paed
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available (
GO42286
)
ALK/RET inhibitor
ALK inhibitor,second generation
Central nervous system cancer
NSW
2031 - Randwick - Sydney Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
NCT04655404
Paed
Phase 1
Recruiting
A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion (
CONNECT1903
)
TRK inhibitor,first generation
Diffuse intrinsic pontine glioma
High-grade glioma
NSW
2031 - Randwick - Sydney Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NCT04323046
Paed
Phase 1
Recruiting
A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition Followed by Adjuvant Checkpoint Inhibition in Children and Young Adults With Recurrent or Progressive High Grade Glioma (HGG)
Nivolumab
anti-PD-1 monoclonal antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
Glioblastoma
Glioma
Malignant glioma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NCT04293562
Paed
Phase 3
Recruiting
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations (
AAML1831
)
AXL/FLT3 inhibitor
anti-CD33 antibody-drug conjugate
liposomal cytarabine/daunorubicin
Acute myeloid leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT04094610
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations (
CA127-1029
)
ALK inhibitor,third generation
ROS1 inhibitor
TRK inhibitor,second generation
Central nervous system cancer
Lymphoma
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (COMPLETED)
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NCT03975829
Paed
Phase 4
Recruiting
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) (
CDRB436G2401
)
BRAF V600 inhibitor
MEK inhibitor
Anaplastic astrocytoma
Anaplastic ganglioglioma
Anaplastic oligodendroglioma
Anaplastic pleomorphic xanthoastrocytoma
Astrocytoma
Central neurocytoma
Desmoplastic infantile astrocytoma
Diffuse astrocytoma
Extra-ventricular Neurocytoma
Gangliocytoma
Ganglioglioma
Glioblastoma
Glioma
Liponeurocytoma
Neurofibromatosis
Oligodendroglioma
Papillary glioneuronal tumour
Pilocytic astrocytoma
Pleomorphic xanthoastrocytoma
Rosette-forming glioneuronal tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
NCT03838042
Paed
Phase 1 / Phase 2
Recruiting
INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt) (
Final4,-18-10-2023
)
HDAC inhibitor,class 1 selective
anti-PD-1 monoclonal antibody
Central nervous system cancer
Solid tumour
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
WA
6009 - Perth - Perth Children's Hospital
NCT03601442
Paed
Available
Managed Access Program (MAP) Cohort Treatment Plan
CCTL019B2003I
to Provide Access for Patients With Out of Specification Leukapheresis Product and/or Out of Specification Manufactured Tisagenlecleucel (CTL019; Kymriah®)
autologous CAR-T-cell therapy,CD19-targeting
Acute lymphoblastic leukaemia
Diffuse large B-cell lymphoma
WA
6150 - Murdoch - Fiona Stanley Hospital (AVAILABLE)
NCT03590171
Paed
Phase 2
Recruiting
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group (
IntReALL-HR-2010
)
Bortezomib
cancer therapy
cancer therapy,proteasome-targeting
proteasome inhibitor
Acute lymphoblastic leukaemia
VIC
3168 - Clayton - Monash Medical Centre
NCT03409081
Paed
No longer available
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) (
2215-CL-9200
)
AXL/FLT3 inhibitor
Acute myeloid leukaemia
ACT
2605 - Garran - The Canberra Hospital
NCT02724163
Paed
Phase 3
Recruiting
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy (
Myechild01
)
anti-CD33 antibody-drug conjugate
Acute myeloid leukaemia
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
2305 - New Lambton Heights - John Hunter Children's Hospital
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
3168 - Clayton - Monash Children's Hospital
QLD
4101 - South Brisbane - Queensland Children's Hospital
SA
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT02670564
Paed
Phase 4
Recruiting
Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) (
NZ-2015-069--ZH-2014-0535
)
Busulfan
Treosulfan
alkylating agent
cancer therapy
cytotoxic chemotherapy
Acute lymphoblastic leukaemia
ACTRN12625001195448
Paed
Phase 1
Not yet recruiting
A Phase I, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of PMCC-COE19 in Patients with CD19-Expressing B-Cell Malignancies (
PLATYPS
)
B-cell lymphoma
Leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
ACTRN12623000104651
Paed
Phase 1
Recruiting
Phase I Trial of the Safety and Efficacy of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours (
DART
)
Fluorouracil
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Ependymoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12622000675729
Paed
Not Applicable
Recruiting
A Phase I Study of the Safety of Autologous GD2-Specific Chimeric Antigen Receptor-Expressing T Cells in Children with Diffuse Midline Glioma (
LEVI’S-CATCH
)
Bevacizumab
CAR-T-cell therapy
CAR-T-cell therapy,GD2-targeting
Cyclophosphamide
Fludarabine
GD2-iCAR-PBT
Radiotherapy
alkylating agent
anti-VEGF monoclonal antibody
antimetabolite
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,GD2-targeting
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cell therapy
cytotoxic chemotherapy
immuno-oncology therapy,VEGF-targeting
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
High-grade glioma
NSW
2031 - Randwick - Prince of Wales Hospital
ACTRN12622000037707
Paed
Phase 2 / Phase 3
Recruiting
A prospective, multicentre, randomised, blinded, two-arm parallel trial of Medicinal Cannabis Products for symptom burden in children with advanced cancer (
MINI
)
Solid tumour
NSW
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
ACTRN12621000246886
Paed
Phase 2
Not yet recruiting
AMLM22/D3-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 3 is investigating the safety and efficacy of an Astrazeneca drug labelled AZD5153 as a maintenance therapy option. (
AMLM22-D3
)
BRD4 inhibitor
Acute myeloid leukaemia
ACTRN12614000552684
Paed
Phase 1
Not yet recruiting
A Phase 1 study of Temozolomide, Irinotecan, and O6BG (O6-Benzylguanine) for Children with Recurrent or Resistant Neuroblastoma (
The-TIO-Study
)
alkylating agent
topoisomerase inhibitor
Neuroblastoma
ACTRN12613000264785
Paed
Phase 2 / Phase 3
Recruiting
Immunogenicity and Safety of a 13-valent pneumococcal conjugate vaccine in paediatric oncology patients (
PCVPON1
)
Solid tumour
NCT02723994
Paed
Phase 2
Active not recruiting
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia (
AALL1521--INCB-18424-269
)
JAK1/JAK2 inhibitor
Leukaemia
NZ
NZ.3210 - Hamilton - Waikato Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (44)
Not yet recruiting (4)
No longer available (2)
Active not recruiting (1)
Recruitment Country and State
NSW (31)
VIC (27)
WA (27)
QLD (22)
NZ (11)
SA (7)
TAS (1)
ACT (1)
Phase
Phase 0 (1)
Phase 1 (8)
Phase 1 / Phase 2 (11)
Phase 2 (12)
Phase 2 / Phase 3 (3)
Phase 3 (8)
Phase 4 (3)
Trial Type
Paed (52)
Paed (1)
Cancer Therapy Class
CD19
10%
CD20
8%
BRAF
8%
RAF
8%
PD-1
8%
PD-1/PD-L1
8%
CDK4
6%
CDK6
6%
CRAF
6%
pan-RAF
6%
CD33
6%
GD2
4%
VEGF
4%
cereblon
4%
mTOR
4%
mTORC1
4%
Bcl2
4%
DNA methyltransferase
4%
KMT2A
4%
JAK1
4%
JAK2
4%
ALK
4%
TRK
4%
AXL
4%
FLT3
4%
CD22
2%
BTK
2%
NFKB
2%
CD7
2%
ROR1
2%
PD-L1
2%
TLR7/TLR8
2%
LAG3
2%
PI3K
2%
PI3K delta
2%
PI3Kalpha
2%
mTORC2
2%
IDH1
2%
IDH1 R132
2%
BCR-ABL1
2%
KIT
2%
PDGFRA
2%
SRC
2%
YES1
2%
VEGFR2
2%
IL-6
2%
CD79b
2%
FACT complex
2%
RET
2%
ROS1
2%
BRAF V600
2%
MEK
2%
HDAC
2%
proteasome
2%
BRD4
2%
Facility
6009 - Perth - Perth Children's Hospital (22)
2031 - Randwick - Sydney Children's Hospital (19)
4101 - South Brisbane - Queensland Children's Hospital (18)
2145 - Westmead - The Children's Hospital at Westmead (15)
3052 - Parkville - Royal Children's Hospital Melbourne (12)
NZ.1023 - Grafton - Starship Children's Hospital (10)
3000 - Melbourne - Peter MacCallum Cancer Centre (8)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (6)
5006 - North Adelaide - Women's and Children's Hospital-Adelaide Cancer Centre (5)
3168 - Clayton - Monash Medical Centre (5)
2305 - New Lambton Heights - John Hunter Children's Hospital (4)
3168 - Clayton - Monash Children's Hospital (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
6000 - Perth - Royal Perth Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
3004 - Melbourne, Southbank - Alfred Health (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
8011 - Christchurch - Christchurch Children's Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2605 - Garran - The Canberra Hospital (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Neurological cancer
Leukaemia
Central nervous system cancer
Glioma
Malignant glioma
Lymphoid leukaemia
Lymphoma
Acute lymphoblastic leukaemia
High-grade glioma
Diffuse intrinsic pontine glioma
H3K27M-mutant glioma
Non-Hodgkin's lymphoma
Acute myeloid leukaemia
Myeloid leukaemia
B-cell malignancy
Mature B-cell malignancy
Sarcoma
Low-grade glioma
Neuroblastic tumour
Peripheral nervous system tumour
B-cell lymphoma
Glioblastoma
Neuroblastoma
B-cell acute lymphoblastic leukaemia/lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Anaplastic astrocytoma
Diffuse midline glioma
Ewing family of tumours
Astrocytoma
Oligodendroglioma
Chronic lymphocytic leukaemia
T-cell acute lymphoblastic leukaemia/lymphoma
Bone cancer
Burkitt lymphoma
Ewing sarcoma
Primitive neuroectodermal tumour
Diffuse hemispheric glioma
Fibrosarcoma
Retinoblastoma
Mixed phenotype acute leukaemia
Alveolar rhabdomyosarcoma
Embryonal rhabdomyosarcoma
Rhabdomyosarcoma
Sclerosing rhabdomyosarcoma
Soft tissue sarcoma
Myeloproliferative neoplasm
Polycythemia vera
Central nervous system primitive neuroectodermal tumour
Medulloblastoma
Differentiated thyroid carcinoma
Endocrine gland cancer
Papillary thyroid cancer
Thyroid cancer
Anaplastic ganglioglioma
Anaplastic oligodendroglioma
Anaplastic pleomorphic xanthoastrocytoma
Benign glioma
Central neurocytoma
Desmoplastic infantile astrocytoma
Diffuse astrocytoma
Extra-ventricular Neurocytoma
Gangliocytoma
Ganglioglioma
Glioneuronal tumour
Liponeurocytoma
Neurofibromatosis
Papillary glioneuronal tumour
Pilocytic astrocytoma
Pleomorphic xanthoastrocytoma
Rosette-forming glioneuronal tumour
Ependymoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy